<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340024</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Major Role of T Regulatory Cells in the Efficiency of Vaccination in General and Immunocompromised Populations: A Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">992</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090992</ELocationID><Abstract><AbstractText>Since their conception with the smallpox vaccine, vaccines used worldwide have mitigated multiple pandemics, including the recent COVID-19 outbreak. Insightful studies have uncovered the complexities of different functional networks of CD4 T cells (T helper 1 (Th1); Th2, Th17) and CD8 T cells (T cytotoxic; Tc), as well as B cell (B<sup>IgM</sup>, B<sup>IgG</sup>, B<sup>IgA</sup> and B<sup>IgE</sup>) subsets, during the response to vaccination. Both T and B cell subsets form central, peripheral, and tissue-resident subsets during vaccination. It has also become apparent that each vaccination forms a network of T regulatory subsets, namely CD4+ CD25+ Foxp3<sup>+</sup> T regulatory (Treg) cells and interleukin-10 (IL-10)-producing CD4+ Foxp3<sup>-</sup> T regulatory 1 (Tr1), as well as many others, which shape the quality/quantity of vaccine-specific IgM, IgG, and IgA antibody production. These components are especially critical for immunocompromised patients, such as older individuals and allograft recipients, as their vaccination may be ineffective or less effective. This review focuses on considering how the pre- and post-vaccination Treg/Tr1 levels influence the vaccination efficacy. Experimental and clinical work has revealed that Treg/Tr1 involvement evokes different immune mechanisms in diminishing vaccine-induced cellular/humoral responses. Alternative steps may be considered to improve the vaccination response, such as increasing the dose, changing the delivery route, and/or repeated booster doses of vaccines. Vaccination may be combined with anti-CD25 (IL-2Rα chain) or anti-programmed cell death protein 1 (PD-1) monoclonal antibodies (mAb) to decrease the Tregs and boost the T/B cell immune response. All of these data and strategies for immunizations are presented and discussed, aiming to improve the efficacy of vaccination in humans and especially in immunocompromised and older individuals, as well as organ transplant patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stepkowski</LastName><ForeName>Stanislaw</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bekbolsynov</LastName><ForeName>Dulat</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3626-4310</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oenick</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurological Surgery, The University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brar</LastName><ForeName>Surina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mierzejewska</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Toledo, Toledo, OH 43614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-0345-7810</Identifier><AffiliationInfo><Affiliation>Department of Urology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekwenna</LastName><ForeName>Obi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Urology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">T regulatory cells</Keyword><Keyword MajorTopicYN="N">immunocompromised</Keyword><Keyword MajorTopicYN="N">vaccine efficacy</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340024</ArticleId><ArticleId IdType="pmc">PMC11436018</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090992</ArticleId><ArticleId IdType="pii">vaccines12090992</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baxby D. Jenner and the control of smallpox. Trans. Med. Soc. Lond. 1996;113:18–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10326082</ArticleId></ArticleIdList></Reference><Reference><Citation>Barquet N., Domingo P. Smallpox: The triumph over the most terrible of the ministers of death. Pt 1Ann. Intern. Med. 1997;127:635–642. doi: 10.7326/0003-4819-127-8_Part_1-199710150-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-127-8_Part_1-199710150-00010</ArticleId><ArticleId IdType="pubmed">9341063</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Polio vaccines: WHO position paper—June 2022. Wkly. Epidemiol. Rec. 2022;97:277–300.</Citation></Reference><Reference><Citation>World Health Organization Measles vaccines: WHO position paper—April 2017. Wkly. Epidemiol. Rec. 2017;92:205–228.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleguezuelos O., James E., Fernandez A., Lopes V., Rosas L.A., Cervantes-Medina A., Cleath J., Edwards K., Neitzey D., Gu W., et al. Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. NPJ Vaccines. 2020;5:22. doi: 10.1038/s41541-020-0174-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0174-9</ArticleId><ArticleId IdType="pmc">PMC7069936</ArticleId><ArticleId IdType="pubmed">32194999</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsmon J., Kate-Ilovitz E., Shaikevich D., Singer Y., Volokhov I., Haim K.Y., Ben-Yedidia T. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. J. Clin. Immunol. 2012;32:595–603. doi: 10.1007/s10875-011-9632-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-011-9632-5</ArticleId><ArticleId IdType="pubmed">22318394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasten-Jolly J., Lawrence D.A. Cellular and Molecular Immunity to Influenza Viruses and Vaccines. Vaccines. 2024;12:389. doi: 10.3390/vaccines12040389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12040389</ArticleId><ArticleId IdType="pmc">PMC11154265</ArticleId><ArticleId IdType="pubmed">38675771</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C., Bai Y., Liu J., Wang Y., He Q., Zhang X., Cheng F., Xu M., Mao Q., Liang Z. Research progress on the quality control of mRNA vaccines. Expert. Rev. Vaccines. 2024;23:570–583. doi: 10.1080/14760584.2024.2354251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2024.2354251</ArticleId><ArticleId IdType="pubmed">38733272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard A.J., Bijker E.M. A guide to vaccinology: From basic principles to new developments. Nat. Rev. Immunol. 2021;21:83–100. doi: 10.1038/s41577-020-00479-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00479-7</ArticleId><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagana A., Visalli G., Di Pietro A., Facciola A. Vaccinomics and adversomics: Key elements for a personalized vaccinology. Clin. Exp. Vaccine Res. 2024;13:105–120. doi: 10.7774/cevr.2024.13.2.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2024.13.2.105</ArticleId><ArticleId IdType="pmc">PMC11091437</ArticleId><ArticleId IdType="pubmed">38752004</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinic M. Vaccine Guidance from Mayo Clinic 2024 [Updated 13 March 2024]  [(accessed on 17 June 2024)].  Available online:  https://www.mayoclinic.org/diseases-conditions/infectious-diseases/in-depth/vaccine-guidance/art-20536857.</Citation></Reference><Reference><Citation>Zimmermann P., Curtis N. Factors That Influence the Immune Response to Vaccination. Clin. Microbiol. Rev. 2019;32:1128. doi: 10.1128/CMR.00084-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00084-18</ArticleId><ArticleId IdType="pmc">PMC6431125</ArticleId><ArticleId IdType="pubmed">30867162</ArticleId></ArticleIdList></Reference><Reference><Citation>Geckin B., Konstantin Fohse F., Dominguez-Andres J., Netea M.G. Trained immunity: Implications for vaccination. Curr. Opin. Immunol. 2022;77:102190. doi: 10.1016/j.coi.2022.102190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102190</ArticleId><ArticleId IdType="pubmed">35597182</ArticleId></ArticleIdList></Reference><Reference><Citation>Danziger-Isakov L., Kumar D., Practice A.I.C.o. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin. Transplant. 2019;33:e13563. doi: 10.1111/ctr.13563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.13563</ArticleId><ArticleId IdType="pubmed">31002409</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez-Zapien G.J., Martinez-Cuazitl A., Sanchez-Brito M., Delgado-Macuil R.J., Atriano-Colorado C., Garibay-Gonzalez F., Sanchez-Monroy V., Lopez-Reyes A., Mata-Miranda M.M. Comparison of the Immune Response in Vaccinated People Positive and Negative to SARS-CoV-2 Employing FTIR Spectroscopy. Cells. 2022;11:3884. doi: 10.3390/cells11233884.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11233884</ArticleId><ArticleId IdType="pmc">PMC9740721</ArticleId><ArticleId IdType="pubmed">36497139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenstrom T., Woodworth J., Dietrich J., Aagaard C., Andersen P., Agger E.M. Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect. Immun. 2012;80:3533–3544. doi: 10.1128/IAI.00550-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00550-12</ArticleId><ArticleId IdType="pmc">PMC3457559</ArticleId><ArticleId IdType="pubmed">22851756</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006;212:28–50. doi: 10.1111/j.0105-2896.2006.00420.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2006.00420.x</ArticleId><ArticleId IdType="pubmed">16903904</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenkel J.M., Masopust D. Tissue-resident memory T cells. Immunity. 2014;41:886–897. doi: 10.1016/j.immuni.2014.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.12.007</ArticleId><ArticleId IdType="pmc">PMC4276131</ArticleId><ArticleId IdType="pubmed">25526304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Pillars article: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999. 401: 708–712. J. Immunol. 2014;192:840–844.</Citation><ArticleIdList><ArticleId IdType="pubmed">24443506</ArticleId></ArticleIdList></Reference><Reference><Citation>von Andrian U.H., Mackay C.R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 2000;343:1020–1034. doi: 10.1056/NEJM200010053431407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200010053431407</ArticleId><ArticleId IdType="pubmed">11018170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F., Lanzavecchia A., Araki K., Ahmed R. From vaccines to memory and back. Immunity. 2010;33:451–463. doi: 10.1016/j.immuni.2010.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC3760154</ArticleId><ArticleId IdType="pubmed">21029957</ArticleId></ArticleIdList></Reference><Reference><Citation>Butcher E.C., Picker L.J. Lymphocyte homing and homeostasis. Science. 1996;272:60–66. doi: 10.1126/science.272.5258.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.272.5258.60</ArticleId><ArticleId IdType="pubmed">8600538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay C.R., Marston W.L., Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. 1990;171:801–817. doi: 10.1084/jem.171.3.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.171.3.801</ArticleId><ArticleId IdType="pmc">PMC2187792</ArticleId><ArticleId IdType="pubmed">2307933</ArticleId></ArticleIdList></Reference><Reference><Citation>Yenyuwadee S., Sanchez-Trincado Lopez J.L., Shah R., Rosato P.C., Boussiotis V.A. The evolving role of tissue-resident memory T cells in infections and cancer. Sci. Adv. 2022;8:eabo5871. doi: 10.1126/sciadv.abo5871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abo5871</ArticleId><ArticleId IdType="pmc">PMC9385156</ArticleId><ArticleId IdType="pubmed">35977028</ArticleId></ArticleIdList></Reference><Reference><Citation>Karin N., Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine. 2018;109:24–28. doi: 10.1016/j.cyto.2018.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2018.02.012</ArticleId><ArticleId IdType="pubmed">29449068</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon R.K., Kondo K. Cell interactions in the induction of tolerance: The role of thymic lymphocytes. Immunology. 1970;18:723–737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1455602</ArticleId><ArticleId IdType="pubmed">4911896</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepkowski S.M., Bitter-Suermann H., Duncan W.R. Induction of transplantation tolerance in rats by spleen allografts. II. Evidence that W3/25+ T suppressor/inducer and OX8+ T suppressor/effector cells are required to mediate specific unresponsiveness. Transplantation. 1987;44:443–448. doi: 10.1097/00007890-198709000-00024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007890-198709000-00024</ArticleId><ArticleId IdType="pubmed">2957840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995;155:1151–1164. doi: 10.4049/jimmunol.155.3.1151.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.155.3.1151</ArticleId><ArticleId IdType="pubmed">7636184</ArticleId></ArticleIdList></Reference><Reference><Citation>Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 2001;167:1245–1253. doi: 10.4049/jimmunol.167.3.1245.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.3.1245</ArticleId><ArticleId IdType="pubmed">11466340</ArticleId></ArticleIdList></Reference><Reference><Citation>Taams L.S., Smith J., Rustin M.H., Salmon M., Poulter L.W., Akbar A.N. Human anergic/suppressive CD4(+)CD25(+) T cells: A highly differentiated and apoptosis-prone population. Eur. J. Immunol. 2001;31:1122–1131. doi: 10.1002/1521-4141(200104)31:4&lt;1122::AID-IMMU1122&gt;3.0.CO;2-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-4141(200104)31:4&lt;1122::AID-IMMU1122&gt;3.0.CO;2-P</ArticleId><ArticleId IdType="pubmed">11298337</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 2001;193:1285–1294. doi: 10.1084/jem.193.11.1285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.193.11.1285</ArticleId><ArticleId IdType="pmc">PMC2193380</ArticleId><ArticleId IdType="pubmed">11390435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori S., Nomura T., Sakaguchi S. Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057–1061. J. Immunol. 2017;198:981–985.</Citation><ArticleIdList><ArticleId IdType="pubmed">28115586</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontenot J.D., Gavin M.A., Rudensky A.Y. Pillars Article: Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells. Nat. Immunol. 2003. 4: 330–336. J. Immunol. 2017;198:986–992.</Citation><ArticleIdList><ArticleId IdType="pubmed">28115587</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Xue Y., Wang J., Dang J., Fang Q., Huang G., Olsen N., Zheng S.G. Negligible Effect of Sodium Chloride on the Development and Function of TGF-beta-Induced CD4(+) Foxp3(+) Regulatory T Cells. Cell Rep. 2019;26:1869–1879.e3. doi: 10.1016/j.celrep.2019.01.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.01.066</ArticleId><ArticleId IdType="pmc">PMC6948355</ArticleId><ArticleId IdType="pubmed">30759396</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S.G., Wang J., Horwitz D.A. Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J. Immunol. 2008;180:7112–7116. doi: 10.4049/jimmunol.180.11.7112.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.11.7112</ArticleId><ArticleId IdType="pubmed">18490709</ArticleId></ArticleIdList></Reference><Reference><Citation>Halim L., Romano M., McGregor R., Correa I., Pavlidis P., Grageda N., Hoong S.J., Yuksel M., Jassem W., Hannen R.F., et al. An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment. Cell Rep. 2017;20:757–770. doi: 10.1016/j.celrep.2017.06.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.06.079</ArticleId><ArticleId IdType="pmc">PMC5529316</ArticleId><ArticleId IdType="pubmed">28723576</ArticleId></ArticleIdList></Reference><Reference><Citation>Romagnani S., Maggi E., Liotta F., Cosmi L., Annunziato F. Properties and origin of human Th17 cells. Mol. Immunol. 2009;47:3–7. doi: 10.1016/j.molimm.2008.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2008.12.019</ArticleId><ArticleId IdType="pubmed">19193443</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y., Tanaka S., Chu F., Nurieva R.I., Martinez G.J., Rawal S., Wang Y.H., Lim H., Reynolds J.M., Zhou X.H., et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat. Med. 2011;17:983–988. doi: 10.1038/nm.2426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2426</ArticleId><ArticleId IdType="pmc">PMC3151340</ArticleId><ArticleId IdType="pubmed">21785430</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhrkamp I., Scheffold A., Heine G. T-cell subsets in allergy and tolerance induction. Eur. J. Immunol. 2023;53:e2249983. doi: 10.1002/eji.202249983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202249983</ArticleId><ArticleId IdType="pubmed">37489248</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Dong L., Zhong J. Immunomodulatory effects of iTr35 cell subpopulation and its research progress. Clin. Exp. Med. 2024;24:41. doi: 10.1007/s10238-024-01303-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-024-01303-5</ArticleId><ArticleId IdType="pmc">PMC10884179</ArticleId><ArticleId IdType="pubmed">38386086</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi S.I., Ishikawa H. Transcriptional Regulation of Differentiation and Functions of Effector T Regulatory Cells. Cells. 2019;8:939. doi: 10.3390/cells8080939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8080939</ArticleId><ArticleId IdType="pmc">PMC6721668</ArticleId><ArticleId IdType="pubmed">31434282</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Liu C., Yu Z., Wu M. New Insights into Regulatory T Cells: Exosome- and Non-Coding RNA-Mediated Regulation of Homeostasis and Resident Treg Cells. Front. Immunol. 2016;7:574. doi: 10.3389/fimmu.2016.00574.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00574</ArticleId><ArticleId IdType="pmc">PMC5138199</ArticleId><ArticleId IdType="pubmed">27999575</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn T., Muschaweckh A. Stability and Maintenance of Foxp3(+) Treg Cells in Non-lymphoid Microenvironments. Front. Immunol. 2019;10:2634. doi: 10.3389/fimmu.2019.02634.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02634</ArticleId><ArticleId IdType="pmc">PMC6868061</ArticleId><ArticleId IdType="pubmed">31798580</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Rudra D. Emerging Functions of Regulatory T Cells in Tissue Homeostasis. Front. Immunol. 2018;9:883. doi: 10.3389/fimmu.2018.00883.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00883</ArticleId><ArticleId IdType="pmc">PMC5989423</ArticleId><ArticleId IdType="pubmed">29887862</ArticleId></ArticleIdList></Reference><Reference><Citation>Najaf Khosravi H., Razi S., Rezaei N. The role of interleukin-2 in graft-versus-host disease pathogenesis, prevention and therapy. Cytokine. 2024;183:156723. doi: 10.1016/j.cyto.2024.156723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2024.156723</ArticleId><ArticleId IdType="pubmed">39173281</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz D.A., Wang J.H., Kim D., Kang C., Brion K., Bickerton S., La Cava A. Nanoparticles loaded with IL-2 and TGF-beta promote transplantation tolerance to alloantigen. Front. Immunol. 2024;15:1429335. doi: 10.3389/fimmu.2024.1429335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1429335</ArticleId><ArticleId IdType="pmc">PMC11310063</ArticleId><ArticleId IdType="pubmed">39131162</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm F., Martin M., Kesselring R., Schiechl G., Geissler E.K., Schlitt H.J., Fichtner-Feigl S. Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation. BMC Gastroenterol. 2012;12:97. doi: 10.1186/1471-230X-12-97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-12-97</ArticleId><ArticleId IdType="pmc">PMC3449180</ArticleId><ArticleId IdType="pubmed">22849659</ArticleId></ArticleIdList></Reference><Reference><Citation>Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J. Immunol. 2009;182:6121–6128. doi: 10.4049/jimmunol.0803646.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0803646</ArticleId><ArticleId IdType="pmc">PMC2698997</ArticleId><ArticleId IdType="pubmed">19414764</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 2001;194:629–644. doi: 10.1084/jem.194.5.629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.194.5.629</ArticleId><ArticleId IdType="pmc">PMC2195935</ArticleId><ArticleId IdType="pubmed">11535631</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandiyan P., Zheng L., Ishihara S., Reed J., Lenardo M.J. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 2007;8:1353–1362. doi: 10.1038/ni1536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1536</ArticleId><ArticleId IdType="pubmed">17982458</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekguc M., Wing J.B., Osaki M., Long J., Sakaguchi S. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA. 2021;118:e2023739118. doi: 10.1073/pnas.2023739118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2023739118</ArticleId><ArticleId IdType="pmc">PMC8325248</ArticleId><ArticleId IdType="pubmed">34301886</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross A.R., Lion J., Poussin K., Glotz D., Mooney N. Inflammation Determines the Capacity of Allogenic Endothelial Cells to Regulate Human Treg Expansion. Front. Immunol. 2021;12:666531. doi: 10.3389/fimmu.2021.666531.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.666531</ArticleId><ArticleId IdType="pmc">PMC8299527</ArticleId><ArticleId IdType="pubmed">34305898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazanova A., Rudd C.E. Programmed cell death 1 ligand (PD-L1) on T cells generates Treg suppression from memory. PLoS Biol. 2021;19:e3001272. doi: 10.1371/journal.pbio.3001272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001272</ArticleId><ArticleId IdType="pmc">PMC8168839</ArticleId><ArticleId IdType="pubmed">34010274</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondelkova K., Vokurkova D., Krejsek J., Borska L., Fiala Z., Ctirad A. Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. Acta Medica. 2010;53:73–77. doi: 10.14712/18059694.2016.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.14712/18059694.2016.63</ArticleId><ArticleId IdType="pubmed">20672742</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocamora-Reverte L., Melzer F.L., Wurzner R., Weinberger B. The Complex Role of Regulatory T Cells in Immunity and Aging. Front. Immunol. 2020;11:616949. doi: 10.3389/fimmu.2020.616949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.616949</ArticleId><ArticleId IdType="pmc">PMC7873351</ArticleId><ArticleId IdType="pubmed">33584708</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman C.J., Szymczak-Workman A.L., Collison L.W., Pillai M.R., Vignali D.A. The development and function of regulatory T cells. Cell. Mol. Life Sci. 2009;66:2603–2622. doi: 10.1007/s00018-009-0026-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-009-0026-2</ArticleId><ArticleId IdType="pmc">PMC2715449</ArticleId><ArticleId IdType="pubmed">19390784</ArticleId></ArticleIdList></Reference><Reference><Citation>Russler-Germain E.V., Rengarajan S., Hsieh C.S. Antigen-specific regulatory T-cell responses to intestinal microbiota. Mucosal Immunol. 2017;10:1375–1386. doi: 10.1038/mi.2017.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2017.65</ArticleId><ArticleId IdType="pmc">PMC5939566</ArticleId><ArticleId IdType="pubmed">28766556</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., McGrady G., Wahl S.M. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 2003;198:1875–1886. doi: 10.1084/jem.20030152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20030152</ArticleId><ArticleId IdType="pmc">PMC2194145</ArticleId><ArticleId IdType="pubmed">14676299</ArticleId></ArticleIdList></Reference><Reference><Citation>Duhen T., Duhen R., Lanzavecchia A., Sallusto F., Campbell D.J. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood. 2012;119:4430–4440. doi: 10.1182/blood-2011-11-392324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-11-392324</ArticleId><ArticleId IdType="pmc">PMC3362361</ArticleId><ArticleId IdType="pubmed">22438251</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch M.A., Thomas K.R., Perdue N.R., Smigiel K.S., Srivastava S., Campbell D.J. T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor beta2. Immunity. 2012;37:501–510. doi: 10.1016/j.immuni.2012.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.05.031</ArticleId><ArticleId IdType="pmc">PMC3501343</ArticleId><ArticleId IdType="pubmed">22960221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Chaudhry A., Kas A., deRoos P., Kim J.M., Chu T.T., Corcoran L., Treuting P., Klein U., Rudensky A.Y. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351–356. doi: 10.1038/nature07674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07674</ArticleId><ArticleId IdType="pmc">PMC2864791</ArticleId><ArticleId IdType="pubmed">19182775</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregori S., Goudy K.S., Roncarolo M.G. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front. Immunol. 2012;3:30. doi: 10.3389/fimmu.2012.00030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00030</ArticleId><ArticleId IdType="pmc">PMC3342353</ArticleId><ArticleId IdType="pubmed">22566914</ArticleId></ArticleIdList></Reference><Reference><Citation>Geginat J., Vasco C., Gruarin P., Bonnal R., Rossetti G., Silvestri Y., Carelli E., Pulvirenti N., Scantamburlo M., Moschetti G., et al. Eomesodermin-expressing type 1 regulatory (EOMES(+) Tr1)-like T cells: Basic biology and role in immune-mediated diseases. Eur. J. Immunol. 2023;53:e2149775. doi: 10.1002/eji.202149775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202149775</ArticleId><ArticleId IdType="pubmed">36653901</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui H., Wang N., Li H., Bian Y., Wen W., Kong X., Wang F. The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: A crosstalk between ancient “Yin-Yang” theory and modern immunology. Cell Commun. Signal. 2024;22:99. doi: 10.1186/s12964-024-01505-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-024-01505-0</ArticleId><ArticleId IdType="pmc">PMC10845554</ArticleId><ArticleId IdType="pubmed">38317142</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X., Zhang J., Cui J., Xu W., Zhao G., Guo C., Yuan W., Zhou X., Ma J. Adaptive plasticity of natural interleukin-35-induced regulatory T cells (Tr35) that are required for T-cell immune regulation. Theranostics. 2024;14:2897–2914. doi: 10.7150/thno.90608.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.90608</ArticleId><ArticleId IdType="pmc">PMC11103508</ArticleId><ArticleId IdType="pubmed">38773985</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastassopoulou C., Ferous S., Medic S., Siafakas N., Boufidou F., Gioula G., Tsakris A. Vaccines for the Elderly and Vaccination Programs in Europe and the United States. Vaccines. 2024;12:566. doi: 10.3390/vaccines12060566.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12060566</ArticleId><ArticleId IdType="pmc">PMC11209271</ArticleId><ArticleId IdType="pubmed">38932295</ArticleId></ArticleIdList></Reference><Reference><Citation>Palatella M., Guillaume S.M., Linterman M.A., Huehn J. The dark side of Tregs during aging. Front. Immunol. 2022;13:940705. doi: 10.3389/fimmu.2022.940705.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.940705</ArticleId><ArticleId IdType="pmc">PMC9398463</ArticleId><ArticleId IdType="pubmed">36016952</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero-Fernandez I., Rosado-Sanchez I., Alvarez-Rios A.I., Galva M.I., De Luna-Romero M., Sanbonmatsu-Gamez S., Perez-Ruiz M., Navarro-Mari J.M., Carrillo-Vico A., Sanchez B., et al. Effect of homeostatic T-cell proliferation in the vaccine responsiveness against influenza in elderly people. Immun. Ageing. 2019;16:14. doi: 10.1186/s12979-019-0154-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-019-0154-y</ArticleId><ArticleId IdType="pmc">PMC6612162</ArticleId><ArticleId IdType="pubmed">31312227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodey B., Bodey B., Jr., Siegel S.E., Kaiser H.E. Involution of the mammalian thymus, one of the leading regulators of aging. In Vivo. 1997;11:421–440.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chougnet C.A., Tripathi P., Lages C.S., Raynor J., Sholl A., Fink P., Plas D.R., Hildeman D.A. A major role for Bim in regulatory T cell homeostasis. J. Immunol. 2011;186:156–163. doi: 10.4049/jimmunol.1001505.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001505</ArticleId><ArticleId IdType="pmc">PMC3066029</ArticleId><ArticleId IdType="pubmed">21098226</ArticleId></ArticleIdList></Reference><Reference><Citation>Raynor J., Sholl A., Plas D.R., Bouillet P., Chougnet C.A., Hildeman D.A. IL-15 Fosters Age-Driven Regulatory T Cell Accrual in the Face of Declining IL-2 Levels. Front. Immunol. 2013;4:161. doi: 10.3389/fimmu.2013.00161.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00161</ArticleId><ArticleId IdType="pmc">PMC3690359</ArticleId><ArticleId IdType="pubmed">23805138</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagger A., Shimojima Y., Goronzy J.J., Weyand C.M. Regulatory T cells and the immune aging process: A mini-review. Gerontology. 2014;60:130–137. doi: 10.1159/000355303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000355303</ArticleId><ArticleId IdType="pmc">PMC4878402</ArticleId><ArticleId IdType="pubmed">24296590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lages C.S., Suffia I., Velilla P.A., Huang B., Warshaw G., Hildeman D.A., Belkaid Y., Chougnet C. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J. Immunol. 2008;181:1835–1848. doi: 10.4049/jimmunol.181.3.1835.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.3.1835</ArticleId><ArticleId IdType="pmc">PMC2587319</ArticleId><ArticleId IdType="pubmed">18641321</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenkranz D., Weyer S., Tolosa E., Gaenslen A., Berg D., Leyhe T., Gasser T., Stoltze L. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J. Neuroimmunol. 2007;188:117–127. doi: 10.1016/j.jneuroim.2007.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.05.011</ArticleId><ArticleId IdType="pubmed">17582512</ArticleId></ArticleIdList></Reference><Reference><Citation>Agius E., Lacy K.E., Vukmanovic-Stejic M., Jagger A.L., Papageorgiou A.P., Hall S., Reed J.R., Curnow S.J., Fuentes-Duculan J., Buckley C.D., et al. Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J. Exp. Med. 2009;206:1929–1940. doi: 10.1084/jem.20090896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20090896</ArticleId><ArticleId IdType="pmc">PMC2737169</ArticleId><ArticleId IdType="pubmed">19667063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregg R., Smith C.M., Clark F.J., Dunnion D., Khan N., Chakraverty R., Nayak L., Moss P.A. The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin. Exp. Immunol. 2005;140:540–546. doi: 10.1111/j.1365-2249.2005.02798.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2005.02798.x</ArticleId><ArticleId IdType="pmc">PMC1809384</ArticleId><ArticleId IdType="pubmed">15932517</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyara M., Yoshioka Y., Kitoh A., Shima T., Wing K., Niwa A., Parizot C., Taflin C., Heike T., Valeyre D., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911. doi: 10.1016/j.immuni.2009.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.03.019</ArticleId><ArticleId IdType="pubmed">19464196</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger B. Vaccines for the elderly: Current use and future challenges. Immun. Ageing. 2018;15:3. doi: 10.1186/s12979-017-0107-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-017-0107-2</ArticleId><ArticleId IdType="pmc">PMC5778733</ArticleId><ArticleId IdType="pubmed">29387135</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista-Duharte A., Pera A., Alino S.F., Solana R. Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects. Int. Immunopharmacol. 2021;96:107761. doi: 10.1016/j.intimp.2021.107761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107761</ArticleId><ArticleId IdType="pubmed">34162139</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M., Rabaan A.A., Alwarthan S., Alhajri M., Halwani M.A., Alshengeti A., Najim M.A., Alwashmi A.S.S., Alshehri A.A., Alshamrani S.A., et al. Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID. Vaccines. 2023;11:699. doi: 10.3390/vaccines11030699.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030699</ArticleId><ArticleId IdType="pmc">PMC10059134</ArticleId><ArticleId IdType="pubmed">36992283</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco A., Song J., Chambers C., Sette A., Grifoni A. SARS-CoV-2 spike-specific regulatory T cells (Treg) expand and develop memory in vaccine recipients suggesting a role for immune regulation in preventing severe symptoms in COVID-19. Autoimmunity. 2023;56:2259133. doi: 10.1080/08916934.2023.2259133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2023.2259133</ArticleId><ArticleId IdType="pubmed">37724524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekbolsynov D., Waack A., Buskey C., Bhadkamkar S., Rengel K., Petersen W., Brown M.L., Sparkle T., Kaw D., Syed F.J., et al. Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech. Vaccines. 2024;12:91. doi: 10.3390/vaccines12010091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12010091</ArticleId><ArticleId IdType="pmc">PMC10819652</ArticleId><ArticleId IdType="pubmed">38250904</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao H., Peng X., Gan L., Feng J., Gao Y., Yang S., Hu X., Zhang L., Yin Y., Wang H., et al. Protective Regulatory T Cell Immune Response Induced by Intranasal Immunization With the Live-Attenuated Pneumococcal Vaccine SPY1 via the Transforming Growth Factor-beta1-Smad2/3 Pathway. Front. Immunol. 2018;9:1754. doi: 10.3389/fimmu.2018.01754.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01754</ArticleId><ArticleId IdType="pmc">PMC6082925</ArticleId><ArticleId IdType="pubmed">30116243</ArticleId></ArticleIdList></Reference><Reference><Citation>Amr A.E.E., Abo-Ghalia M.H., Moustafa G.O., Al-Omar M.A., Nossier E.S., Elsayed E.A. Design, Synthesis and Docking Studies of Novel Macrocyclic Pentapeptides as Anticancer Multi-Targeted Kinase Inhibitors. Molecules. 2018;23:2416. doi: 10.3390/molecules23102416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23102416</ArticleId><ArticleId IdType="pmc">PMC6222410</ArticleId><ArticleId IdType="pubmed">30241374</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou M.L., Chen Z.H., Teng Y.Y., Liu S.Y., Jia Y., Zhang K.W., Sun Z.L., Wu J.J., Yuan Z.D., Feng Y., et al. The Smad Dependent TGF-beta and BMP Signaling Pathway in Bone Remodeling and Therapies. Front. Mol. Biosci. 2021;8:593310. doi: 10.3389/fmolb.2021.593310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.593310</ArticleId><ArticleId IdType="pmc">PMC8131681</ArticleId><ArticleId IdType="pubmed">34026818</ArticleId></ArticleIdList></Reference><Reference><Citation>Brezar V., Godot V., Cheng L., Su L., Levy Y., Seddiki N. T-Regulatory Cells and Vaccination “Pay Attention and Do Not Neglect Them”: Lessons from HIV and Cancer Vaccine Trials. Vaccines. 2016;4:30. doi: 10.3390/vaccines4030030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines4030030</ArticleId><ArticleId IdType="pmc">PMC5041024</ArticleId><ArticleId IdType="pubmed">27608046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappellano G., Abreu H., Casale C., Dianzani U., Chiocchetti A. Nano-Microparticle Platforms in Developing Next-Generation Vaccines. Vaccines. 2021;9:606. doi: 10.3390/vaccines9060606.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9060606</ArticleId><ArticleId IdType="pmc">PMC8228777</ArticleId><ArticleId IdType="pubmed">34198865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.C., Zhang A.J., Li C., Chen Y., Liu F., Zhao Y., Chu H., Fong C.H., Wang P., Lau S.Y., et al. Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges. NPJ Vaccines. 2021;6:95. doi: 10.1038/s41541-021-00359-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00359-8</ArticleId><ArticleId IdType="pmc">PMC8339132</ArticleId><ArticleId IdType="pubmed">34349128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P.H., Wong W.I., Wang Y.L., Hsieh M.P., Lu C.W., Liang C.Y., Jui S.H., Wu F.Y., Chen P.J., Yang H.C. Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection. Mucosal Immunol. 2018;11:1239–1253. doi: 10.1038/s41385-018-0004-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-018-0004-9</ArticleId><ArticleId IdType="pubmed">29467445</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinc R. Leishmania Vaccines: The Current Situation with Its Promising Aspect for the Future. Korean J. Parasitol. 2022;60:379–391. doi: 10.3347/kjp.2022.60.6.379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3347/kjp.2022.60.6.379</ArticleId><ArticleId IdType="pmc">PMC9806502</ArticleId><ArticleId IdType="pubmed">36588414</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller A., Solnick J.V. Inflammation, immunity, and vaccine development for Helicobacter pylori. Helicobacter. 2011;16((Suppl. S1)):26–32. doi: 10.1111/j.1523-5378.2011.00877.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-5378.2011.00877.x</ArticleId><ArticleId IdType="pubmed">21896082</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyck L., Wilk M.M., Raverdeau M., Misiak A., Boon L., Mills K.H. Anti-PD-1 inhibits Foxp3(+) Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model. Cancer Immunol. Immunother. 2016;65:1491–1498. doi: 10.1007/s00262-016-1906-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-016-1906-6</ArticleId><ArticleId IdType="pmc">PMC11028992</ArticleId><ArticleId IdType="pubmed">27680570</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg A., Canniff J., Rouphael N., Mehta A., Mulligan M., Whitaker J.A., Levin M.J. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. J. Immunol. 2017;199:604–612. doi: 10.4049/jimmunol.1700290.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700290</ArticleId><ArticleId IdType="pmc">PMC5505810</ArticleId><ArticleId IdType="pubmed">28607114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellars M.C., Wu C.J., Fritsch E.F. Cancer vaccines: Building a bridge over troubled waters. Cell. 2022;185:2770–2788. doi: 10.1016/j.cell.2022.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.035</ArticleId><ArticleId IdType="pmc">PMC9555301</ArticleId><ArticleId IdType="pubmed">35835100</ArticleId></ArticleIdList></Reference><Reference><Citation>Strum S., Andersen M.H., Svane I.M., Siu L.L., Weber J.S. State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers. Am. Soc. Clin. Oncol. Educ. Book. 2024;44:e438592. doi: 10.1200/EDBK_438592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/EDBK_438592</ArticleId><ArticleId IdType="pubmed">38669611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty N.G., Chattopadhyay S., Mehrotra S., Chhabra A., Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum. Immunol. 2004;65:794–802. doi: 10.1016/j.humimm.2004.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2004.05.012</ArticleId><ArticleId IdType="pubmed">15336780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahl K., Sparwasser T. In vivo depletion of FoxP3+ Tregs using the DEREG mouse model. Methods Mol. Biol. 2011;707:157–172. doi: 10.1007/978-1-61737-979-6_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61737-979-6_10</ArticleId><ArticleId IdType="pubmed">21287334</ArticleId></ArticleIdList></Reference><Reference><Citation>Klages K., Mayer C.T., Lahl K., Loddenkemper C., Teng M.W., Ngiow S.F., Smyth M.J., Hamann A., Huehn J., Sparwasser T. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010;70:7788–7799. doi: 10.1158/0008-5472.CAN-10-1736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-10-1736</ArticleId><ArticleId IdType="pubmed">20924102</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka A., Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur. J. Immunol. 2019;49:1140–1146. doi: 10.1002/eji.201847659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847659</ArticleId><ArticleId IdType="pubmed">31257581</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon I., Amann M., Goubier A., Arce Vargas F., Zervas D., Qing C., Henry J.Y., Ghorani E., Akarca A.U., Marafioti T., et al. CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat. Cancer. 2020;1:1153–1166. doi: 10.1038/s43018-020-00133-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-020-00133-0</ArticleId><ArticleId IdType="pmc">PMC7116816</ArticleId><ArticleId IdType="pubmed">33644766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolini A., Ferrari P. Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy. Front. Immunol. 2024;15:1353787. doi: 10.3389/fimmu.2024.1353787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1353787</ArticleId><ArticleId IdType="pmc">PMC11306065</ArticleId><ArticleId IdType="pubmed">39119332</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Franco F., Tsui Y.C., Xie X., Trefny M.P., Zappasodi R., Mohmood S.R., Fernandez-Garcia J., Tsai C.H., Schulze I., et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat. Immunol. 2020;21:298–308. doi: 10.1038/s41590-019-0589-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0589-5</ArticleId><ArticleId IdType="pmc">PMC7043937</ArticleId><ArticleId IdType="pubmed">32066953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Xiao L., Liu L., Ye L., Su P., Bi E., Wang Q., Yang M., Qian J., Yi Q. CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33:1001–1012.e5. doi: 10.1016/j.cmet.2021.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.02.015</ArticleId><ArticleId IdType="pmc">PMC8102368</ArticleId><ArticleId IdType="pubmed">33691090</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Hartman C.L., Li L., Albert C.J., Si F., Gao A., Huang L., Zhao Y., Lin W., Hsueh E.C., et al. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Sci. Transl. Med. 2021;13:aaz6314. doi: 10.1126/scitranslmed.aaz6314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaz6314</ArticleId><ArticleId IdType="pubmed">33790024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Kumar S., Dahiya S., Wang F., Wu J., Newick K., Han R., Samanta A., Beier U.H., Akimova T., et al. Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity. EBioMedicine. 2016;13:99–112. doi: 10.1016/j.ebiom.2016.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2016.10.018</ArticleId><ArticleId IdType="pmc">PMC5264272</ArticleId><ArticleId IdType="pubmed">27769803</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbecke R., Cohen J.I., Oxman M.N. Herpes Zoster Vaccines. J. Infect. Dis. 2021;224:S429–S442. doi: 10.1093/infdis/jiab387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab387</ArticleId><ArticleId IdType="pmc">PMC8482024</ArticleId><ArticleId IdType="pubmed">34590136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Z., Wang X., Dong K., Zhang H., Bu Z., Ye L., Yang C. Blockage of regulatory T cells augments induction of protective immune responses by influenza virus-like particles in aged mice. Microbes Infect. 2017;19:626–634. doi: 10.1016/j.micinf.2017.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2017.08.013</ArticleId><ArticleId IdType="pmc">PMC5726911</ArticleId><ArticleId IdType="pubmed">28899815</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeli S., Hassan S.S., Yap W.B. Multi-Epitope Peptide-Based and Vaccinia-Based Universal Influenza Vaccine Candidates Subjected to Clinical Trials. Malays. J. Med. Sci. 2020;27:10–20. doi: 10.21315/mjms2020.27.2.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.21315/mjms2020.27.2.2</ArticleId><ArticleId IdType="pmc">PMC7409566</ArticleId><ArticleId IdType="pubmed">32788837</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutigliano J.A., Sharma S., Morris M.Y., Oguin T.H., 3rd, McClaren J.L., Doherty P.C., Thomas P.G. Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells. J. Virol. 2014;88:1636–1651. doi: 10.1128/JVI.02851-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02851-13</ArticleId><ArticleId IdType="pmc">PMC3911576</ArticleId><ArticleId IdType="pubmed">24257598</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli E., Boni M., Di Luca D., Salvatori D., Vita A., Cassai E. A combined bovine herpesvirus 1 gB-gD DNA vaccine induces immune response in mice. Comp. Immunol. Microbiol. Infect. Dis. 2005;28:155–166. doi: 10.1016/j.cimid.2004.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cimid.2004.10.001</ArticleId><ArticleId IdType="pubmed">15582691</ArticleId></ArticleIdList></Reference><Reference><Citation>Toka F.N., Suvas S., Rouse B.T. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. J. Virol. 2004;78:13082–13089. doi: 10.1128/JVI.78.23.13082-13089.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.23.13082-13089.2004</ArticleId><ArticleId IdType="pmc">PMC525021</ArticleId><ArticleId IdType="pubmed">15542660</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuichi Y., Tokuyama H., Ueha S., Kurachi M., Moriyasu F., Kakimi K. Depletion of CD25+CD4+T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization. World J. Gastroenterol. 2005;11:3772–3777. doi: 10.3748/wjg.v11.i24.3772.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v11.i24.3772</ArticleId><ArticleId IdType="pmc">PMC4316033</ArticleId><ArticleId IdType="pubmed">15968737</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaron B., Maranghi E., Leclerc C., Majlessi L. Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS ONE. 2008;3:e2833. doi: 10.1371/journal.pone.0002833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002833</ArticleId><ArticleId IdType="pmc">PMC2475666</ArticleId><ArticleId IdType="pubmed">18665224</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn K.M., McHugh R.S., Rich F.J., Goldsack L.M., de Lisle G.W., Buddle B.M., Delahunt B., Kirman J.R. Inactivation of CD4+ CD25+ regulatory T cells during early mycobacterial infection increases cytokine production but does not affect pathogen load. Immunol. Cell Biol. 2006;84:467–474. doi: 10.1111/j.1440-1711.2006.01460.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1711.2006.01460.x</ArticleId><ArticleId IdType="pubmed">16869940</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinoza Mora M.R., Steeg C., Tartz S., Heussler V., Sparwasser T., Link A., Fleischer B., Jacobs T. Depletion of regulatory T cells augments a vaccine-induced T effector cell response against the liver-stage of malaria but fails to increase memory. PLoS ONE. 2014;9:e104627. doi: 10.1371/journal.pone.0104627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104627</ArticleId><ArticleId IdType="pmc">PMC4130546</ArticleId><ArticleId IdType="pubmed">25115805</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner-Spitzer E., Wagner A., Paulke-Korinek M., Kollaritsch H., Heinz F.X., Redlberger-Fritz M., Stiasny K., Fischer G.F., Kundi M., Wiedermann U. Tick-borne encephalitis (TBE) and hepatitis B nonresponders feature different immunologic mechanisms in response to TBE and influenza vaccination with involvement of regulatory T and B cells and IL-10. J. Immunol. 2013;191:2426–2436. doi: 10.4049/jimmunol.1300293.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300293</ArticleId><ArticleId IdType="pubmed">23872054</ArticleId></ArticleIdList></Reference><Reference><Citation>Litjens N.H., Boer K., Betjes M.G. Identification of circulating human antigen-reactive CD4+ FOXP3+ natural regulatory T cells. J. Immunol. 2012;188:1083–1090. doi: 10.4049/jimmunol.1101974.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101974</ArticleId><ArticleId IdType="pubmed">22190183</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Wang L., Niu W., Wu Y., Zhang J., Meng G. Increased CD4+CD25+FoxP3+ regulatory T cells in the blood of nonresponders after standard hepatitis B surface antigen vaccine immunization. Clin. Immunol. 2008;127:265–266. doi: 10.1016/j.clim.2007.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2007.11.010</ArticleId><ArticleId IdType="pubmed">18304878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Wang S., Zhang J., Wang L., Wu Y. Expression of PD-1 is up-regulated in CD4+CD25+ FoxP3+ regulatory T cell of non-responders after hepatitis B surface antigen vaccine immunization. Clin. Immunol. 2008;129:176–177. doi: 10.1016/j.clim.2008.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.07.007</ArticleId><ArticleId IdType="pubmed">18707923</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale J., Farez M., Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann. Neurol. 2008;64:187–199. doi: 10.1002/ana.21438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21438</ArticleId><ArticleId IdType="pubmed">18655096</ArticleId></ArticleIdList></Reference><Reference><Citation>Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., Kim H.J., Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 2007;178:6092–6099. doi: 10.4049/jimmunol.178.10.6092.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.10.6092</ArticleId><ArticleId IdType="pubmed">17475834</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010;32:129–140. doi: 10.1016/j.immuni.2009.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.11.009</ArticleId><ArticleId IdType="pubmed">20079667</ArticleId></ArticleIdList></Reference><Reference><Citation>Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., Sanz I. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044–3056. doi: 10.1002/art.22810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22810</ArticleId><ArticleId IdType="pubmed">17763423</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell K.A., Asare A., Kirk A.D., Gisler T.D., Bourcier K., Suthanthiran M., Burlingham W.J., Marks W.H., Sanz I., Lechler R.I., et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Investig. 2010;120:1836–1847. doi: 10.1172/JCI39933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI39933</ArticleId><ArticleId IdType="pmc">PMC2877933</ArticleId><ArticleId IdType="pubmed">20501946</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A., Ellis G., Pallant C., Lopes A.R., Khanna P., Peppa D., Chen A., Blair P., Dusheiko G., Gill U., et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J. Immunol. 2012;189:3925–3935. doi: 10.4049/jimmunol.1103139.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103139</ArticleId><ArticleId IdType="pmc">PMC3480715</ArticleId><ArticleId IdType="pubmed">22972930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemoine S., Morva A., Youinou P., Jamin C. Human T cells induce their own regulation through activation of B cells. J. Autoimmun. 2011;36:228–238. doi: 10.1016/j.jaut.2011.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2011.01.005</ArticleId><ArticleId IdType="pubmed">21316922</ArticleId></ArticleIdList></Reference><Reference><Citation>Macatangay B.J., Szajnik M.E., Whiteside T.L., Riddler S.A., Rinaldo C.R. Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS ONE. 2010;5:e9852. doi: 10.1371/journal.pone.0009852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009852</ArticleId><ArticleId IdType="pmc">PMC2844424</ArticleId><ArticleId IdType="pubmed">20352042</ArticleId></ArticleIdList></Reference><Reference><Citation>Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 1999;190:995–1004. doi: 10.1084/jem.190.7.995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.190.7.995</ArticleId><ArticleId IdType="pmc">PMC2195650</ArticleId><ArticleId IdType="pubmed">10510089</ArticleId></ArticleIdList></Reference><Reference><Citation>Durando P., Iudici R., Alicino C., Alberti M., de Florentis D., Ansaldi F., Icardi G. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum. Vaccin. 2011;7((Suppl. S1)):29–40. doi: 10.4161/hv.7.0.14560.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.7.0.14560</ArticleId><ArticleId IdType="pubmed">21245655</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke S.N., Ovsyannikova I.G., Poland G.A., Kennedy R.B. Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses. Exp. Gerontol. 2019;124:110632. doi: 10.1016/j.exger.2019.110632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2019.110632</ArticleId><ArticleId IdType="pmc">PMC6849399</ArticleId><ArticleId IdType="pubmed">31201918</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista-Duharte A., Tellez-Martinez D., Fuentes D.L.P., Carlos I.Z. Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal. Pharmacol. Res. 2018;129:237–250. doi: 10.1016/j.phrs.2017.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2017.11.026</ArticleId><ArticleId IdType="pubmed">29175113</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndure J., Flanagan K.L. Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front. Microbiol. 2014;5:477. doi: 10.3389/fmicb.2014.00477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2014.00477</ArticleId><ArticleId IdType="pmc">PMC4161046</ArticleId><ArticleId IdType="pubmed">25309517</ArticleId></ArticleIdList></Reference><Reference><Citation>Curreri A., Sankholkar D., Mitragotri S., Zhao Z. RNA therapeutics in the clinic. Bioeng. Transl. Med. 2023;8:e10374. doi: 10.1002/btm2.10374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10374</ArticleId><ArticleId IdType="pmc">PMC9842029</ArticleId><ArticleId IdType="pubmed">36684099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartkowiak T., Curran M.A. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front. Oncol. 2015;5:117. doi: 10.3389/fonc.2015.00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2015.00117</ArticleId><ArticleId IdType="pmc">PMC4459101</ArticleId><ArticleId IdType="pubmed">26106583</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartkowiak T., Singh S., Yang G., Galvan G., Haria D., Ai M., Allison J.P., Sastry K.J., Curran M.A. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc. Natl. Acad. Sci. USA. 2015;112:E5290–E5299. doi: 10.1073/pnas.1514418112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1514418112</ArticleId><ArticleId IdType="pmc">PMC4586868</ArticleId><ArticleId IdType="pubmed">26351680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock T.N.J. CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cell Mol. Immunol. 2022;19:14–22. doi: 10.1038/s41423-021-00734-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00734-4</ArticleId><ArticleId IdType="pmc">PMC8752810</ArticleId><ArticleId IdType="pubmed">34282297</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y., Li R., Qian L., Liu F., Xu R., Meng F., Ke Y., Shao J., Yu L., Liu Q., et al. Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination. Cancer Sci. 2021;112:4490–4500. doi: 10.1111/cas.15145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.15145</ArticleId><ArticleId IdType="pmc">PMC8586665</ArticleId><ArticleId IdType="pubmed">34537997</ArticleId></ArticleIdList></Reference><Reference><Citation>Paston S.J., Brentville V.A., Symonds P., Durrant L.G. Cancer Vaccines, Adjuvants, and Delivery Systems. Front. Immunol. 2021;12:627932. doi: 10.3389/fimmu.2021.627932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.627932</ArticleId><ArticleId IdType="pmc">PMC8042385</ArticleId><ArticleId IdType="pubmed">33859638</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J.F., Punt C.J., Lesterhuis W.J., Sutmuller R.P., Brouwer H.M., Scharenborg N.M., Klasen I.S., Hilbrands L.B., Figdor C.G., de Vries I.J., et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: A phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 2010;16:5067–5078. doi: 10.1158/1078-0432.CCR-10-1757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-10-1757</ArticleId><ArticleId IdType="pubmed">20736326</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A.P.Y., Cohen C.A., Leung N.H.L., Fang V.J., Gangappa S., Sambhara S., Levine M.Z., Iuliano A.D., Perera R., Ip D.K.M., et al. Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults. NPJ Vaccines. 2021;6:25. doi: 10.1038/s41541-021-00289-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00289-5</ArticleId><ArticleId IdType="pmc">PMC7886864</ArticleId><ArticleId IdType="pubmed">33594050</ArticleId></ArticleIdList></Reference><Reference><Citation>Winokur P., El Sahly H.M., Mulligan M.J., Frey S.E., Rupp R., Anderson E.J., Edwards K.M., Bernstein D.I., Schmader K., Jackson L.A., et al. Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. Vaccine. 2021;39:1339–1348. doi: 10.1016/j.vaccine.2020.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.11.051</ArticleId><ArticleId IdType="pmc">PMC8504682</ArticleId><ArticleId IdType="pubmed">33485646</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelton S.I., Divino V., Shah D., Mould-Quevedo J., DeKoven M., Krishnarajah G., Postma M.J. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017-2018 Influenza Season. Vaccines. 2020;8:446. doi: 10.3390/vaccines8030446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030446</ArticleId><ArticleId IdType="pmc">PMC7563546</ArticleId><ArticleId IdType="pubmed">32784684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali L., Budhiraja P., Gea-Banacloche J. COVID-19 in kidney transplantation-implications for immunosuppression and vaccination. Front. Med. 2022;9:1060265. doi: 10.3389/fmed.2022.1060265.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1060265</ArticleId><ArticleId IdType="pmc">PMC9727141</ArticleId><ArticleId IdType="pubmed">36507509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tylicki L., Debska-Slizien A., Muchlado M., Slizien Z., Golebiewska J., Dabrowska M., Biedunkiewicz B. Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients. Vaccines. 2021;10:56. doi: 10.3390/vaccines10010056.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010056</ArticleId><ArticleId IdType="pmc">PMC8779302</ArticleId><ArticleId IdType="pubmed">35062717</ArticleId></ArticleIdList></Reference><Reference><Citation>Icardi G., Orsi A., Ceravolo A., Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia licensed micro injection system. Hum. Vaccin. Immunother. 2012;8:67–75. doi: 10.4161/hv.8.1.18419.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.8.1.18419</ArticleId><ArticleId IdType="pmc">PMC3350142</ArticleId><ArticleId IdType="pubmed">22293531</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S.K., Mahajan P., Singh N.K., Gupta A., Aggarwal R., Rappuoli R., Johri A.K. New-age vaccine adjuvants, their development, and future perspective. Front. Immunol. 2023;14:1043109. doi: 10.3389/fimmu.2023.1043109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1043109</ArticleId><ArticleId IdType="pmc">PMC9998920</ArticleId><ArticleId IdType="pubmed">36911719</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster R.G., Govorkova E.A. Continuing challenges in influenza. Ann. N. Y. Acad. Sci. 2014;1323:115–139. doi: 10.1111/nyas.12462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12462</ArticleId><ArticleId IdType="pmc">PMC4159436</ArticleId><ArticleId IdType="pubmed">24891213</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlicevic M., Marmiroli N., Maestri E. Immunomodulatory peptides-A promising source for novel functional food production and drug discovery. Peptides. 2022;148:170696. doi: 10.1016/j.peptides.2021.170696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2021.170696</ArticleId><ArticleId IdType="pubmed">34856531</ArticleId></ArticleIdList></Reference><Reference><Citation>Du P.Y., Gandhi A., Bawa M., Gromala J. The ageing immune system as a potential target of senolytics. Oxf. Open Immunol. 2023;4:iqad004. doi: 10.1093/oxfimm/iqad004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqad004</ArticleId><ArticleId IdType="pmc">PMC10191675</ArticleId><ArticleId IdType="pubmed">37255929</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Tchkonia T., Pirtskhalava T., Gower A.C., Ding H., Giorgadze N., Palmer A.K., Ikeno Y., Hubbard G.B., Lenburg M., et al. The Achilles’ heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell. 2015;14:644–658. doi: 10.1111/acel.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12344</ArticleId><ArticleId IdType="pmc">PMC4531078</ArticleId><ArticleId IdType="pubmed">25754370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>